Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study.

Active vitamin D Calcium Chronic hypoparathyroidism Chronic kidney disease Kidney stones Nephrocalcinosis Nephrolithiasis

Journal

Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864

Informations de publication

Date de publication:
04 2021
Historique:
received: 24 11 2020
accepted: 03 02 2021
pubmed: 12 3 2021
medline: 20 4 2021
entrez: 11 3 2021
Statut: ppublish

Résumé

Chronic hypoparathyroidism managed with conventional treatment, comprising oral administration of calcium and active vitamin D, has been associated with renal complications, including nephrolithiasis and nephrocalcinosis. Further larger-scale studies are needed to examine these risks. This study evaluated the risk of nephrolithiasis and nephrocalcinosis in patients with chronic hypoparathyroidism. A retrospective cohort study using a managed care claims database in the United States from January 2007 to June 2017. Included patients were those with chronic hypoparathyroidism (excluding those receiving parathyroid hormone) and randomly selected patients without hypoparathyroidism over a maximum of 5-year follow-up. The main outcome measures were nephrolithiasis, identified by diagnosis codes or procedure codes for removing kidney stones, and nephrocalcinosis, identified by diagnosis codes. The nephrolithiasis analyses included 8097 adult patients with hypoparathyroidism and 40,485 adult patients without hypoparathyroidism. After excluding patients with a diagnosis of nephrocalcinosis at baseline, nephrocalcinosis analyses included 8051 patients with hypoparathyroidism and 40,466 patients without hypoparathyroidism. During 5 years of follow-up, patients with chronic hypoparathyroidism had significantly increased risk of nephrolithiasis and nephrocalcinosis in Kaplan-Meier analysis compared with patients without hypoparathyroidism (both P < 0.001). In the adjusted analyses, chronic hypoparathyroidism was associated with higher risks of nephrolithiasis (hazard ratio [HR], 1.81; 95% confidence interval [CI] 1.60-2.04) and nephrocalcinosis (HR, 6.94; 95% CI 4.41-10.92). A sensitivity analysis restricted to patients with at least one kidney imaging examination showed that 2.6% of patients (n = 59) with hypoparathyroidism and 0.5% of patients (n = 20) without hypoparathyroidism (ratio, 5.5; P < 0.001) developed nephrocalcinosis. This large retrospective cohort study showed a statistically significant and clinically meaningful increased risk of nephrolithiasis and nephrocalcinosis in patients who have chronic hypoparathyroidism compared with those who do not have chronic hypoparathyroidism.

Identifiants

pubmed: 33704680
doi: 10.1007/s12325-021-01649-2
pii: 10.1007/s12325-021-01649-2
pmc: PMC8004511
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

1946-1957

Références

J Clin Endocrinol Metab. 2012 Dec;97(12):4507-14
pubmed: 23043192
J Bone Miner Res. 2013 Nov;28(11):2277-85
pubmed: 23661265
Endocr Pract. 2014 Jul;20(7):671-9
pubmed: 24449664
Eur J Endocrinol. 2002 Feb;146(2):215-22
pubmed: 11834431
J Clin Endocrinol Metab. 2016 Jun;101(6):2273-83
pubmed: 26943719
Kidney Int. 2005 Oct;68(4):1808-14
pubmed: 16164658
Eur J Endocrinol. 2015 Aug;173(2):G1-20
pubmed: 26160136
J Clin Endocrinol Metab. 2016 Aug;101(8):3045-53
pubmed: 27186861
Endocrinol Metab Clin North Am. 2018 Dec;47(4):889-900
pubmed: 30390820
J Clin Endocrinol Metab. 2016 Jun;101(6):2300-12
pubmed: 26943721
N Engl J Med. 2008 Jul 24;359(4):391-403
pubmed: 18650515
J Bone Miner Res. 2018 May;33(5):822-831
pubmed: 29281760
J Endocrinol Invest. 2018 Oct;41(10):1221-1226
pubmed: 29516386
J Bone Miner Res. 2015 Sep;30(9):1738-44
pubmed: 25753591
J Clin Endocrinol Metab. 2013 Mar;98(3):989-94
pubmed: 23348401
Kidney Int Rep. 2016 Dec 31;2(3):366-379
pubmed: 29318214
Front Pediatr. 2018 Apr 12;6:98
pubmed: 29707529
J Bone Miner Res. 2011 Oct;26(10):2317-37
pubmed: 21812031
Clin Endocrinol (Oxf). 2018 Jun;88(6):838-847
pubmed: 29520810
J Bone Miner Res. 2013 Dec;28(12):2570-6
pubmed: 23737456
J Clin Endocrinol Metab. 2016 Jun;101(6):2313-24
pubmed: 26938200
Endocr Pract. 2011 Mar-Apr;17 Suppl 1:18-25
pubmed: 21134871
Osteoporos Int. 2014 Jun;25(6):1717-26
pubmed: 24687385
Front Endocrinol (Lausanne). 2017 Jan 16;7:172
pubmed: 28138323
Eur J Endocrinol. 2019 Mar;180(3):P1-P22
pubmed: 30540559

Auteurs

Markus Ketteler (M)

Department of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus, Stuttgart, Germany. Markus.Ketteler@rbk.de.
University of Split School of Medicine (USSM), Split, Croatia. Markus.Ketteler@rbk.de.

Kristina Chen (K)

Shire Human Genetic Therapies, Inc., A Takeda Company, Lexington, MA, USA.

Elvira O Gosmanova (EO)

Division of Nephrology and Hypertension, Albany Medical College, Albany, NY, USA.

James Signorovitch (J)

Analysis Group, Inc., Boston, MA, USA.

Fan Mu (F)

Analysis Group, Inc., Boston, MA, USA.

Joshua A Young (JA)

Analysis Group, Inc., Boston, MA, USA.

Nicole Sherry (N)

Shire Human Genetic Therapies, Inc., A Takeda Company, Lexington, MA, USA.

Lars Rejnmark (L)

Aarhus University and Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH